Form 6-K — CureVac N.V.: Update Regarding Timeline of Programs, J.P. Morgan Healthcare Conference (2022)

Summary

A Form 6-K report of foreign private issuer filed by CureVac N.V. with the U.S. Securities and Exchange Commission for the month of January, 2022, Commission File Number 001-39446. The report is titled an update regarding the timeline of CureVac programs in the context of the J.P. Morgan Healthcare Conference. It describes timelines for second-generation infectious disease candidates developed with GlaxoSmithKline Biologicals SA, including CV2CoV and an influenza candidate, the oncology candidate CV8102, and molecular therapy work in liver fibrosis. The report is signed January 7, 2022 and incorporated by reference into Form F-3, File No. 333-259613.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE
ISSUER

PURSUANT TO RULE 13a-16
OR 15d-16 OF THE

SECURITIES EXCHANGE ACT
OF 1934

For the month of January, 2022

Commission File Number: 001-39446

CureVac N.V.

( Exact Name of Registrant as Specified in Its
Charter )

Friedrich-Miescher-Strasse 15, 72076

Tübingen, Germany

+49 7071 9883 0

(Address of principal executive office)

Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F | x | Form 40-F | ¨

Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes | ¨ | No | x

Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes | ¨ | No | x

Update Regarding Timeline of CureVac N.V. Programs in the Context
of the J.P. Morgan Healthcare Conference

CureVac N.V. (the “Company”) published today its timeline
for the following programs:

· | Second-Generation Infectious Disease Program in Collaboration with GlaxoSmithKline Biologicals SA (“GSK”). In prophylactic
vaccines, the Company is advancing its second-generation mRNA vaccine candidate, CV2CoV, against coronavirus (SARS-CoV-2) in collaboration
with GSK. CV2CoV is the first representative of the Company’s anticipated broad second-generation COVID-19 vaccine program. The
vaccine candidate, presently at preclinical development stage, is a non-chemically modified mRNA, encoding the prefusion stabilized full-length
spike protein of the SARS-CoV-2 virus, and formulated within Lipid Nanoparticles. The Company expects to start a Phase 1 clinical trial
assessing CV2CoV in the first quarter of 2022. Furthermore, the Company’s candidates addressing relevant COVID-19 variants are currently
in preclinical testing. Additionally, the Company expects to start assessing a modified second-generation COVID-19 mRNA vaccine candidate
in a Phase 1 trial in the third quarter of 2022. Based on Phase 1 study results, the Company conservatively estimates that a pivotal study
for the advanced clinical development of a COVID-19 vaccine candidate may be initiated in the fourth quarter of 2022.

Within the broader second-generation infectious disease program,
which the Company is developing in collaboration with GSK, the first non-COVID-19 vaccine candidate is an influenza vaccine. The Company
is currently assessing the first mRNA influenza vaccine candidates in a preclinical model and expects to start a Phase 1 trial with a
chemically non-modified mRNA candidate in the first quarter of 2022 and a Phase 1 trial with a modified mRNA candidate in the third quarter
of 2022.

· | RNA-Based Therapeutics in Oncology. The Company’s lead oncology candidate, CV8102, is a complex of single-stranded non-coding
RNA which has been optimized to maximize activation of cellular receptors that normally detect viral pathogens entering the cells (such
as toll-like receptor 7, toll-like receptor 8 and retinoic acid inducible gene I), mimicking a viral infection of the tumor. In February
2021, the Company initiated the expansion of its Phase 1 study to confirm the safety, tolerability and efficacy of CV8102 at a 600μg
dose, the selected dose to be advanced in a Phase 2 clinical trial. The expansion part of the Phase 1 trial completed enrollment in October
2021 and involves 40 trial participants, with 10 in the single-agent cohort and 30 in the combination cohort with anti-PD-1. Comprehensive
data from the expansion part of the study is expected to be published in the fourth quarter of 2022.

Furthermore, the Company anticipates providing proof-of concept
data for selected antigens in cancer vaccines with a focus on T cell mediated responses in the future. Selection of suitable clinical
candidate(s) for a first clinical study is expected to occur in the first half of 2022.

· | Molecular Therapy. In molecular therapies, the Company published preclinical mouse data in liver fibrosis in the Journal of
Hepatology in August 2021, which provides the first preclinical data demonstrating the therapeutic applicability of mRNA-encoded HNF4A
in the treatment of liver fibrosis and cirrhosis.

The Company further expects to publish data from its collaboration
with the Schepens Eye Research Institute of Mass. Eye and Ear in the first half of 2022.

The information included in this Form 6-K (including Exhibit 99.1)
is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-259613).

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CUREVAC N.V.
By: | /s/ Franz-Werner Haas, LLD, LLM
Chief Executive Officer

Date: January 7, 2022

File and source

File

SEC_CVAC_6-K_filed2022-01-07_0001104659-22-002254.htm

Size

17,805 bytes

SHA-256

c6533a6f290e94a31925aee942c8fdc02a73304aaf1a4d9d49b86f3b241bd8d8

Our copy

SEC_CVAC_6-K_filed2022-01-07_0001104659-22-002254.htm

Original

www.sec.gov